As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

Background and Aim: Hepatic dysfunction is a common cause of morbidity and mortality in bone marrow transplant recipients. During the complex clinical management of these patients, liver biopsies ...

You might not think much about what makes a liver healthy or unhealthy. And when your liver starts to become unhealthy, you ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

1 Introduction. In the 1980s, Ludwig et al. first reported on 20 patients with unexplained non-alcoholic fatty liver disease (NAFLD), whose liver biopsy specimens showed significant fat changes ...

Nonalcoholic fatty liver disease (NAFLD) is being diagnosed with increasing frequency, and can progress to end-stage liver disease. NAFLD is seen in obese patients in the absence of significant ...

It’s normal to feel anxious before you get a liver biopsy. But the process is usually quick and not very painful. Learn more about this procedure.

Results. In the final cohort of 406 patients followed for a median of 3.7 years (interquartile range: 4.8 years), 35 patients died, 41 developed hepatic decompensation, and 70 experienced a liver ...

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. This study aimed to investigate ...

This Review summarizes current understanding of nonalcoholic fatty liver disease, which is now accepted as the hepatic manifestation of metabolic syndrome. The authors consider the evaluation of ...

A 73-year-old man was admitted because of 22 months of recurrent fever and progressive hypodensities in the liver. A liver-biopsy specimen showed nonnecrotizing granulomas. A diagnosis was made.